Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBlue Cross Blue Shield MI Acitretin Prior Auth | O…
    Ask Trek AI about this page
    Currentblue cross blue shield - michiganPolicy N/A

    Acitretin prior authorization and coverage summary

    Customize your policy alerts

    Sign up for all blue cross blue shield - michigan policy alerts

    Know when blue cross blue shield - michigan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This document lists prior authorization (PA) and step therapy (ST) requirements for acitretin and other drugs under the Blue Cross Blue Shield of Michigan Medicare Plus Blue Group PPO and Prescription Blue Group PDP formulary; it applies to plan members and their prescribing providers seeking coverage for these medications.

    Policy Summary
    Payerblue cross blue shield - michigan
    PolicyAcitretin prior authorization and coverage summary
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateAug 1, 2026
    Last ReviewAug 1, 2026
    Next Review DateAug 1, 2026
    Key ActionSubmit a prior authorization request and required clinical documentation to obtain coverage for acitretin.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    1 Yearcoverage duration for Acitretin when authorized
    PAauthorization type applied to Acitretin
    No Prereqprerequisite therapy requirement for Acitretin
    CURRENT

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    document status

    Coverage Criteria and Product Summaries

    Acitretin - Initial Authorization

    Covered when administrative/clinical PA criteria are met.

    Acitretin authorization requirements: Acitretin is subject to prior authorization; indications = all medically-accepted indications; coverage duration = One Year; prerequisite therapy: Criteria DOES NOT require use of a prerequisite Part D drug.

    Off-Label Uses, Exclusion Criteria, Required Medical Information, Age and Prescriber Restrictions are listed as N/A in this section.

    Product PA summary criteria

    Covered when PA criteria summaries and product-specific prerequisite requirements are met as listed per product.

    Alecensa: Indications: All medically-accepted indications; Coverage Duration: 1 Year; Prerequisite Therapy: Criteria DOES NOT require use of a prerequisite Part D drug.

    chunk 18

    Alosetron: Indications: All medically-accepted indications; Coverage Duration: 1 YEAR; Prerequisite Therapy: Criteria DOES NOT require use of a prerequisite Part D drug.

    chunk 19

    Prolastin-c (Alpha-1 PI): Requires diagnosis of necrotizing panniculitis or alpha-1 antitrypsin deficiency with FEV1 < 80% predicted; documentation of congenital deficiency consistent with phenotypes PiZZ, PiZ (null), or PI(null,null); patients 18 years or older; Prerequisite Therapy: Criteria does NOT require use of a prerequisite Part D drug.FEV1 < 80% predicted

    chunk 20

    Alunbrig: Coverage for ALK-positive metastatic disease; Prerequisite Therapy: trial of crizotinib required (Criteria DOES require use of a prerequisite Part D drug).

    chunk 22

    Arcalyst: Coverage for recurrent inflammatory condition; Prerequisite Therapy: inflammatory drug in combination with colchicine required (Criteria DOES require use of a prerequisite Part D drug).

    chunk 23

    Arikayce: Indications: All medically-accepted indications; Coverage Duration: 1 YEAR; Prerequisite Therapy: Criteria DOES NOT require use of a prerequisite Part D drug.

    chunk 24

    Auvelity: Coverage for major depressive disorder requires trial of another generic formulary antidepressant (Prerequisite Part D drug required).

    chunk 30

    Auryxia: Indications: All medically-accepted indications; Coverage Duration: One Year; Prerequisite Therapy: Criteria DOES NOT require use of a prerequisite Part D drug.

    chunk 29

    Ayvakit: Indications: All medically-accepted indications; Coverage Duration: One Year; Prerequisite Therapy: Criteria DOES NOT require use of a prerequisite Part D drug.

    chunk 33

    Balversa: Coverage for locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 alterations requires trial of at least one prior systemic therapy (Criteria DOES require use of a prerequisite Part D drug).

    chunk 34

    Banzel (rufinamide): Coverage requires trial of divalproex or similar anticonvulsant prior to approval (Criteria DOES require use of a prerequisite Part D drug).

    chunk 36

    Product PA summary (chunks 36-55)

    Product-level PA notes and prerequisite therapy requirements as listed.

    Product entries: Multiple products listed with PA criteria shorthand: Indications = All Medically-accepted Indications; Off-Label Uses = N/A; Exclusion Criteria = N/A; Required Medical Information varies by product; Age/Prescriber Restrictions vary; Coverage Duration often 1 YEAR; Other Criteria often list prerequisite Part D drug trials or specific prior therapy requirements.

    See individual product entries for specific prerequisite therapy or documentation requirements (e.g., chunks 36–55).

    Bronchitol: required documentation

    Bronchitol specific: Coverage requires documentation that the member has passed the Bronchitol tolerance test.

    Coverage Duration: 1 YEAR; Prerequisite Therapy: Criteria DOES NOT require use of a prerequisite Part D drug.

    Brukinsa: indication-specific prerequisites

    Brukinsa indication-specific prerequisites: Coverage for mantle cell lymphoma (MCL) requires a trial of Calquence; coverage for relapsed/refractory marginal zone lymphoma (MZL) requires a trial of at least one anti-CD20–based regimen; coverage for relapsed/refractory follicular lymphoma (FL) requires combination use with obinutuzumab and trial of two or more lines of systemic therapy; coverage for CLL/SLL requires a trial of Calquence or Imbruvica. Coverage Duration: 1 YEAR. Criteria DOES require use of a prerequisite Part D drug.

    chunk 55

    Brukinsa

    Brukinsa (product summary)

    Brukinsa prerequisites: Coverage for MCL requires a trial of Calquence; for relapsed/refractory MZL requires a trial of at least one anti-CD20–based regimen; for relapsed/refractory FL requires combination with obinutuzumab and trial of two or more prior systemic therapy lines; for CLL/SLL requires a trial of Calquence or Imbruvica. Coverage duration: 1 YEAR.

    Criteria DOES require use of a prerequisite Part D drug.

    Budesonide ER

    Budesonide ER (product summary)

    Budesonide exclusions: Coverage will not be provided for maintenance of remission in ulcerative colitis.

    Prerequisite Therapy: Criteria DOES NOT require use of a prerequisite Part D drug.

    Bysanti

    Bysanti (product summary)

    Bysanti prerequisites: Coverage for schizophrenia in adults requires trials of lurasidone and paliperidone; for other indications requires trial of at least two listed generic antipsychotics (e.g., aripiprazole, asenapine, lurasidone, olanzapine, paliperidone, quetiapine, risperidone, ziprasidone).

    Coverage Duration: PLAN YEAR; Criteria DOES require use of a prerequisite Part D drug.

    Cablivi

    Cablivi (product summary)

    Cablivi prerequisites: Coverage for acquired thrombotic thrombocytopenic purpura (aTTP); prerequisite therapy: immunosuppressive therapy noted.

    Criteria DOES NOT require use of a prerequisite Part D drug.

    Cabometyx

    Cabometyx (product summary)

    Cabometyx prerequisites: Coverage for first-line advanced renal cell carcinoma requires combination use with nivolumab; coverage for hepatocellular carcinoma (HCC) requires a trial of sorafenib; coverage for locally advanced or metastatic differentiated thyroid cancer that is radioactive iodine‑refractory or ineligible requires a trial of VEGFR‑targeted therapy.

    Coverage Duration: One Year; Criteria DOES require use of a prerequisite Part D drug.

    Calcipotriene

    Calcipotriene (product summary)

    Calcipotriene prerequisites: Requires trial of at least one generic topical agent prior to coverage.

    Criteria DOES require use of a prerequisite Part D drug.

    Calquence

    Calquence (product summary)

    Calquence prerequisites: Coverage for mantle cell lymphoma (MCL) requires that the patient has received at least one prior therapy for MCL; coverage for previously untreated MCL in patients ineligible for HSCT requires combination use with bendamustine and rituximab.

    Coverage Duration: ONE YEAR; Criteria DOES require use of a prerequisite Part D drug.

    Caprelsa

    Caprelsa (product summary)

    Caprelsa prerequisites: Indications: All medically-accepted indications; Prerequisite Therapy: Criteria DOES NOT require use of a prerequisite Part D drug.

    Coverage Duration: One Year.

    Cayston

    Cayston (product summary)

    Cayston prerequisites: Indications: All medically-accepted indications; Prerequisite Therapy: Criteria DOES NOT require use of a prerequisite Part D drug.

    Coverage Duration: 1 YEAR.

    Product PA summaries (partial)

    Product-level PA summaries (selection from document).

    Cayston: Indications: All medically-accepted indications; Coverage Duration: 1 YEAR; Prerequisite Therapy: Does not require Part D drug.

    chunk 73

    Cerdelga: Indications: All medically-accepted indications; Coverage Duration: One Year; Prerequisite Therapy: Does not require Part D drug.

    chunk 75

    Cholbam: Indications: All medically-accepted indications; Coverage Duration: 1 Year; Prerequisite Therapy: Does not require Part D drug.

    chunk 77

    Clomiphene: Indications: All medically-accepted indications; Coverage Duration: 1 YEAR; Prerequisite Therapy: Does not require Part D drug.

    Cosentyx - Indication-specific criteria

    Cosentyx: Covered when INDICATION-SPECIFIC requirements are met

    Cosentyx_general: Coverage requires diagnosis-specific criteria (e.g., active psoriatic arthritis, chronic moderate-to-severe plaque psoriasis; ankylosing spondylitis and non‑radiographic axial spondyloarthritis require trial of one NSAID; reauthorization requires documentation of positive clinical response). Cannot be used in combination with another biologic or targeted DMARD for the same indication.

    chunks 93-94

    Dalfampridine - MS ambulatory improvement

    Dalfampridine: Covered when ALL of the following are met

    Dalfampridine_general: Coverage requires documentation of a baseline Timed 25‑Foot Walk (T25FW) test prior to initiation; use is excluded if the patient is wheelchair bound or becomes wheelchair bound.

    chunk 103

    Cotellic - Melanoma

    Cotellic: Covered when criteria met for melanoma

    Cotellic_general: Coverage for unresectable or metastatic melanoma with BRAF V600E or V600K mutation; prior vemurafenib listed as prerequisite therapy.

    chunk 97

    Cresemba / Cystaran - Duration

    Cresemba and Cystaran coverage notes

    Cresemba_Cystaran_duration: Coverage duration specified as 1 YEAR for Cresemba and Cystaran; indications listed as all medically-accepted indications.

    chunks 99,101

    Danyelza - Neuroblastoma

    Danyelza: Coverage when criteria met for neuroblastoma

    Danyelza_general: Coverage for relapsed or refractory high‑risk neuroblastoma requires response or stable disease to prior therapy; Prerequisite Therapy: Criteria DOES require use of a prerequisite Part D drug.

    chunk 105

    Diacomit: Coverage criteria

    Diacomit coverage requires ALL of the following

    Diacomit baseline requirements: Coverage requires trial of two generic anticonvulsants AND combination use with clobazam.

    chunk 114

    Dihydroergotamine: Coverage criteria

    Dihydroergotamine nasal spray coverage requires ALL of the following

    Triptan trial requirement: Coverage requires trial of two triptans on the formulary: one oral triptan and one non‑oral triptan.

    chunk 116

    Doptelet: Coverage criteria

    Doptelet coverage notes

    Doptelet indication: Coverage for treatment of chronic immune thrombocytopenia per PA details.

    chunk 118

    Dupixent: Indication-specific criteria

    Dupixent coverage requires specific diagnosis and prior therapies depending on indication

    Dupixent_general: Dupixent cannot be used in combination with another biologic or targeted DMARD for the same indication; reauthorization requires documentation of positive clinical response; multiple age minimums and indication‑specific prior therapy/biomarker requirements apply.

    chunks 124–126

    Eosinophilic asthma: Diagnosis of eosinophilic asthma with eosinophil count >=150 cells/µL at initiation AND failure of specified controller regimens; additional controller therapy trials required.>=150 cells/µL

    chunks 125–126

    COPD add-on maintenance: Uncontrolled moderate to severe COPD with eosinophil count >=300 cells/µL AND patient is currently receiving and will continue LABA, LAMA, and an inhaled corticosteroid unless contraindicated; reauthorization requires documentation of positive clinical response.>=300 cells/µL

    COPD — add-on maintenance

    Coverage conditions described in snippet for specific indications (example: COPD, PN, CSU, AFRS):

    COPD add-on maintenance: Requires diagnosis of uncontrolled, moderate to severe COPD AND eosinophil count >=300 cells/µL AND patient is currently receiving and will continue LABA, LAMA, and an inhaled corticosteroid unless contraindicated.eosinophils >= 300 cells/µL

    Reauthorization requires documentation of positive clinical response to therapy.

    PN / CSU / AFRS — indication-specific

    Other indication-specific requirements noted:

    Prurigo nodularis (PN): Coverage requires diagnosis of PN; reauthorization requires documentation of positive clinical response to therapy.

    chunk 126

    Chronic spontaneous urticaria (CSU): Coverage requires diagnosis of CSU AND symptoms despite H1 antihistamine treatment AND trial of at least one second‑generation antihistamine; reauthorization requires documentation of positive clinical response.

    chunk 126

    Allergic fungal rhinosinusitis (AFRS): Coverage requires diagnosis of AFRS AND history of sino‑nasal surgery; reauthorization requires documentation of positive clinical response.

    chunk 126

    Epidiolex — seizure indications

    Epidiolex seizure-related coverage conditions:

    Lennox-Gastaut syndrome: Coverage requires trial of two generic alternatives for treatment of seizures; coverage duration 1 YEAR; reauthorization requires positive clinical response.

    chunk 145

    Dravet syndrome: Coverage requires trial of two of the following: valproic acid, clobazam, or topiramate; coverage duration 1 YEAR; reauthorization requires positive clinical response.

    chunk 145

    Seizures associated with tuberous sclerosis complex: Coverage requires trial of two generic alternatives for treatment of seizures; coverage duration 1 YEAR; reauthorization requires positive clinical response.

    chunk 145

    Product PA summaries

    Each product entry lists PA criteria details; common elements include 'All medically-accepted indications' and coverage duration often one year; prerequisite therapy requirements vary by product and indication.

    Product PA summaries: Many product entries indicate Prior Authorization applies, Coverage Duration commonly 1 YEAR, and Prerequisite Therapy is specified for some indications (examples: Epidiolex, Eulexin, Fanapt, etc.).

    chunks 145,148,151,154,157,159,161,163

    Eulexin — Initial Coverage Criteria

    Eulexin (flutamide/leuprolide context): Covered when ALL of the following are met

    Eulexin prerequisites: Coverage requires a trial of generic bicalutamide prior to approval; Coverage Duration: 1 YEAR; Prerequisite Therapy: Criteria DOES require use of a prerequisite Part D drug.

    chunk 163

    Fanapt — Initial Coverage Criteria

    Covered when ALL of the following are met

    Fanapt prerequisites: Coverage for schizophrenia requires trial of two generic formulary atypical antipsychotics (e.g., quetiapine, risperidone, ziprasidone); Prerequisite Therapy: Criteria DOES require use of a prerequisite Part D drug.

    chunk 165

    Fasenra — Indication-specific Criteria

    Covered for specified eosinophilic conditions when the numeric and diagnostic criteria below are met

    Eosinophilic asthma: Diagnosis of eosinophilic asthma with eosinophil count >=150 cells/µL at initiation AND failure to maintain control after systemic corticosteroids or high‑dose inhaled corticosteroids plus trial of an additional asthma controller (leukotriene modifier, LABA, or LAMA). Coverage duration one year; reauthorization requires documentation of positive clinical response.>=150 cells/µL

    chunks 167,169

    EGPA: Diagnosis of eosinophilic granulomatosis with polyangiitis (EGPA) with history or presence of asthma AND two typical EGPA features (e.g., histopathologic eosinophilic vasculitis, neuropathy, pulmonary infiltrates, allergic rhinitis/nasal polyps, cardiomyopathy).

    chunk 169

    Hypereosinophilic syndrome (HES): Diagnosis of HES with eosinophil count >=1000 cells/µL at initiation of treatment; reauthorization requires documentation of positive clinical response.>=1000 cells/µL

    Firazyr — Coverage Criteria

    Firazyr age requirement: Patient is 18 years of age or older.age >=18

    Coverage Duration: 1 YEAR; chunk 175

    Forteo — Initial Coverage Criteria

    Forteo prerequisites: Coverage requires trial of specified prior osteoporosis therapies (e.g., oral bisphosphonate or IV bisphosphonate if intolerant) and other named agents per policy; T‑score referenced at or below -2.5 may apply.T-score <= -2.5

    chunk 179

    Fotivda coverage

    Product-specific coverage notes (excerpted):

    Fotivda - advanced RCC: Coverage for advanced renal cell carcinoma requires a trial of two or more prior systemic therapies and use of a prerequisite Part D drug (Criteria DOES require use of a prerequisite Part D drug).

    chunk 181

    Fruzaqla coverage

    Product-specific coverage notes (excerpted):

    Fruzaqla - metastatic colorectal cancer: Coverage for metastatic colorectal cancer (mCRC) requires trials of fluoropyrimidine‑, oxaliplatin‑, and irinotecan‑based chemotherapy and an anti‑VEGF therapy; Prerequisite Therapy: Criteria DOES require use of a prerequisite Part D drug.

    chunk 183

    Coverage duration

    Products with specified coverage duration:

    One-year coverage examples: Examples of products with one‑year coverage duration where specified include: Fulphila, Gattex, Fingolimod (Gilenya), and others.

    chunks 185,189,192,199

    GLP-1 agonists coverage

    GLP-1 agonists inclusion criteria: Coverage allowed for type 2 diabetes mellitus when documentation of diagnosis or lab criteria is provided (A1c >=6.5% OR fasting plasma glucose >=126 mg/dL OR 2‑hour plasma glucose >=200 mg/dL during OGTT); excluded if used for weight loss only.A1c >=6.5% OR FPG >=126 mg/dL OR 2‑hour PG >=200 mg/dL

    chunk 197

    Product PA summaries

    General summary for listed products in this segment

    General PA conditions: Indications generally limited to medically‑accepted indications; Coverage Duration commonly 1 YEAR; Prerequisite Therapy requirements vary by product; Off‑label uses and Exclusion Criteria often marked N/A unless specified.

    chunks 199,201,203,205,207,210,212,216

    Growth hormone coverage duration

    Growth hormone (Genotropin) coverage

    Growth hormone duration: Pediatrics = 1 YEAR; Adults = LIFETIME.

    chunk 203

    Humira (adalimumab) criteria

    Humira (adalimumab) PA details

    Humira prerequisites: Coverage for specific indications requires specified prior therapies (e.g., DMARD trial for RA; NSAID trial for ankylosing spondylitis) and documented diagnosis of active disease; reauthorization requires documentation of positive clinical response; cannot be used in combination with another biologic or targeted DMARD for the same condition.

    chunks 212–214

    General listings (multiple products)

    Products listed with PA criteria summaries — stance is generally coverage for medically-accepted indications with PA conditions where specified.

    General product PA template: Indications: All medically‑accepted indications; Off‑Label Uses: N/A; Exclusion Criteria: N/A; Required Medical Information: varies by product; Coverage Duration: commonly 1 YEAR when stated; Prerequisite Therapy: noted per product.

    chunk 216

    Ibrance - combination therapy and prerequisite therapy

    Covered when ALL of the following are met:

    Ibrance - HR+/HER2- advanced/metastatic breast cancer: Used in combination with an aromatase inhibitor as initial endocrine‑based therapy OR with fulvestrant in patients with disease progression following endocrine therapy; for endocrine‑resistant, PIK3CA‑mutated disease requires combination with inavolisib and fulvestrant following recurrence on or after completing adjuvant endocrine therapy; Criteria DOES require use of a prerequisite Part D drug.

    chunk 221

    Iclusig - indication-specific coverage and prior therapy requirements

    Coverage conditions vary by indication:

    Iclusig indications: Coverage for newly diagnosed Ph+ ALL requires combination with chemotherapy; monotherapy allowed for T315I‑positive Ph+ ALL when no other kinase inhibitors are indicated; coverage for T315I‑positive CML provided; accelerated/blast phase CML covered when no other kinase inhibitors are indicated; coverage for other chronic phase CML indications requires trial of at least two prior kinase inhibitors. Criteria DOES require use of a prerequisite Part D drug for some indications.

    chunk 225

    Imkeldi - oral formulation limitation

    Covered when ALL of the following are met:

    Imkeldi formulation requirement: Coverage for all indications requires that the patient is unable to swallow the tablet formulation OR is unable to achieve the prescribed dose with the tablet formulation; other indication‑specific requirements apply as noted in the product entry.

    chunk 231

    Product PA summaries

    Per-product PA summary entries (detailed criteria not present in this excerpt).

    Product-level PA summary: Each listed product entry provides: Indications = All medically‑accepted indications (unless otherwise noted); Off‑Label Uses = N/A; Exclusion Criteria = N/A; Required Medical Information = varies; Coverage Duration = commonly 1 YEAR; some products note prerequisite therapy requirements. Detailed 'Criteria Details' are referenced in the full policy.

    chunk 235

    Inlyta-specific coverage condition

    Inlyta first-line RCC: Coverage for first‑line treatment of advanced renal cell carcinoma requires combination use with avelumab or pembrolizumab; other indications may require a trial of one prior systemic therapy.

    chunk 239

    Inqovi prerequisite therapy

    Inqovi prerequisite therapy: Coverage requires a trial with azacitidine prior to approval; Coverage Duration: 1 YEAR.

    chunk 241

    Isotretinoin prerequisite therapy

    Isotretinoin prerequisite: Coverage requires the trial of an oral therapy (details truncated in excerpt); Prerequisite Therapy: Criteria DOES require use of a prerequisite Part D drug.

    chunk 248

    Ivermectin TABS 3MG — Initial coverage criteria

    Covered when criteria details are met as listed for the product entry

    Ivermectin TABS 3MG coverage: Indications: All FDA‑approved indications; Off‑Label Uses: N/A; Exclusion Criteria: N/A; Required Medical Information: N/A; Age/Prescriber Restrictions: N/A; Coverage Duration: 1 YEAR; Prerequisite Therapy: Criteria DOES NOT require use of a prerequisite Part D drug.

    chunk 254

    The policy lists coverage for Acitretin as subject to prior authorization (PA). Indications are stated as All Medically-accepted Indications, with coverage duration = One Year. The entry explicitly notes that Off-Label Uses = N/A, Exclusion Criteria = N/A, and that no specific required medical information, age, or prescriber restrictions are specified in this section. The policy also states that Prerequisite Therapy: Criteria DOES NOT require use of a prerequisite Part D drug for Acitretin.

    Multiple product-level PA summaries in this segment follow a consistent template: indications are generally listed as All Medically-accepted Indications, Off-Label Uses = N/A, and Exclusion Criteria = N/A unless otherwise specified. Coverage durations are frequently set to 1 Year. Where present, product entries list prerequisite therapy requirements (e.g., some require prior Part D drug trials) but many do not require a prerequisite Part D drug. Examples in this extract include Alecensa and Alosetron (Off-Label Uses = N/A; Exclusion Criteria = N/A; Coverage Duration = 1 Year) and Humulin R U-500, Increlex, and Ivermectin TABS 3MG whose entries similarly list Off-Label Uses = N/A and Coverage Duration = 1 Year.

    Several product entries explicitly record Off-Label Uses = N/A, indicating there is no coverage described for off‑label indications within these summaries. Examples in the excerpt include the anticonvulsant/related entries (rufinamide) and multiple biologic and specialty products where the Off-Label Uses field is recorded as N/A. Where off‑label or exclusion guidance is relevant it is called out separately in the product note.

    The Budesonide ER product entry explicitly states that coverage will not be provided for maintenance of remission in ulcerative colitis. The remainder of the Budesonide ER entry follows the standard PA summary format (Off-Label Uses = N/A; Prerequisite Therapy does not require a prerequisite Part D drug), but the maintenance‑of‑remission exclusion is an explicit limitation for this product.

    The Tadalafil (Cialis) product entry contains an explicit exclusion: coverage is not provided for tadalafil in situations where patients are receiving nitrate therapy. This entry also requires a diagnosis (benign prostatic hyperplasia) for the listed tadalafil tablet strengths and otherwise follows the standard PA template (Off-Label Uses = N/A; Coverage Duration = 1 Year).

    The Dalfampridine (extended release) entry includes a specific exclusion: use is excluded if the patient is wheelchair bound or becomes wheelchair bound. In addition, initiation requires documentation of a baseline Timed 25‑Foot Walk (T25FW) prior to starting therapy; the PA summary marks Off-Label Uses = N/A and notes no prerequisite Part D drug is required.

    Dupixent (dupilumab) entries specify that the product cannot be used in combination with another biologic or targeted DMARD indicated for the same condition. The Dupixent entry otherwise lists indication‑specific age and diagnostic/prior‑therapy requirements and a coverage duration = 1 Year; Off-Label Uses = N/A is also recorded.

    The policy repeatedly prohibits combination biologic/targeted DMARD therapy for the same indication in multiple product entries. For example, Ebglyss and Enbrel each state Exclusion Criteria: CANNOT BE USED IN COMBINATION WITH ANOTHER BIOLOGIC OR TARGETED DMARD INDICATED FOR THE SAME CONDITION. Dupixent contains the same prohibition. These combination‑therapy exclusions are applied per product where noted in the PA summaries.

    Across many product summaries in this extract the fields Off-Label Uses = N/A and Exclusion Criteria = N/A are repeated when no off‑label coverage or exclusion is specified. These N/A entries appear in products ranging from antiepileptics and biologics to oncology and supportive agents, reflecting that off‑label coverage is not defined in the summary where N/A is recorded.

    Fasenra (benralizumab) entry states that it cannot be used in combination with another biologic or targeted DMARD indicated for the same condition. The Fasenra PA also includes numeric initiation thresholds (e.g., eosinophil counts) and requires documentation of clinical response for reauthorization where indicated.

    GLP‑1 agonists in this segment are excluded if used for the treatment of weight loss only. For ongoing treatment of type 2 diabetes mellitus the GLP‑1 entry requires submission of records confirming T2DM diagnosis or lab evidence (e.g., A1c ≥6.5%; FPG ≥126 mg/dL; or 2‑hour PG ≥200 mg/dL). Coverage duration is listed as 1 Year and the entry records Off-Label Uses = N/A.

    Humira (adalimumab) product summaries reiterate the prohibition on concurrent use with another biologic or targeted DMARD for the same condition: CANNOT BE USED IN COMBINATION WITH ANOTHER BIOLOGIC OR TARGETED DMARD INDICATED FOR THE SAME. Humira entries also specify indication‑specific prior therapy requirements (e.g., DMARDs for RA) and reauthorization requires documentation of positive clinical response.

    The document repeatedly records Off-Label Uses = N/A for many products in the extract; these N/A statements appear across product summaries (e.g., antiepileptics, oncology, and specialty biologics) indicating that no off‑label coverage details are provided in those entries.

    Additional product entries within this segment likewise list Off-Label Uses = N/A. When off‑label uses or exclusions are relevant, the policy calls them out explicitly; otherwise the N/A designation is used consistently in the PA summaries.

    The Ivermectin TABS 3MG entry in this extract contains no specific exclusion criteria; its PA summary records Indications = All FDA‑approved Indications, Off-Label Uses = N/A, and Exclusion Criteria = N/A, with Coverage Duration = 1 Year and an explicit note that Prerequisite Therapy: Criteria DOES NOT require use of a prerequisite Part D drug.

    What Providers Must Do

    Prior Authorization

    Acitretin — prior authorization required

    Acitretin is subject to prior authorization. Clinical and/or administrative PA criteria must be met before coverage is provided; coverage duration when authorized is one year.

    Prior Authorization

    Alecensa — PA and duration

    Alecensa requires prior authorization; indications are listed as all medically-accepted and coverage duration is 1 year.

    Prior Authorization

    Alosetron — PA and duration

    Alosetron (alosetron hydrochloride) is subject to prior authorization; indications are listed as all medically-accepted and coverage duration is 1 year.

    Initial Therapy / Start of Therapy Conditions

    Reauthorization and Duration Rules

    Step Therapy (Prerequisite Therapy) Table

    DrugStep requirement
    Alunbrig
    Prior trial of crizotinib required before Alunbrig coverage
    DrugStep requirement
    Auvelity
    Trial of another generic formulary antidepressant required before Auvelity coverage
    DrugStep requirement
    Balversa
    Trial of at least one prior systemic therapy required before Balversa coverage
    DrugStep requirement
    Arcalyst
    Prior inflammatory drug in combination with colchicine required before Arcalyst coverage
    DrugStep requirement
    Rufinamide (Banzel)
    Trial of divalproex or similar anticonvulsant required before coverage
    ContextRequirement
    Prerequisite Part D drug (general note)
    Coverage for certain products requires trial of divalproex or other specified prerequisite Part D drug as noted
    DrugStep / combination requirement
    Braftovi
    Requires combination use with specified agents for certain indications (e.g., binimetinib; vemurafenib + cobimetinib; cetuximab + fluorouracil-based chemotherapy) before coverage
    ExamplesStep / prerequisite requirement
    Brukinsa — MCL / MZL / FL / CLL
    Requires trial of specified agents prior to coverage (examples: Calquence for MCL; anti‑CD20 regimens for MZL; obinutuzumab + prior systemic therapy for FL; Calquence or Imbruvica for CLL)
    DrugStep requirement
    Cobenfy
    Prior antipsychotics required before coverage for schizophrenia
    DrugStep requirement
    Copiktra
    Requires at least two prior therapies before coverage
    ProductStep requirement
    Cosentyx
    Prior NSAID trial required for ankylosing spondylitis and non‑radiographic axial spondyloarthritis before coverage
    DrugPrerequisite therapy
    Cotellic
    Vemurafenib listed as prerequisite therapy (per product-specific combination requirements)
    Example productStep requirements
    Diacomit (example)
    Trial of two generic anticonvulsants and combination use with clobazam required before coverage
    Example productStep requirement
    Dihydroergotamine (nasal)
    Trial of two triptans on the formulary (one oral, one non‑oral) required before coverage
    ContextRequirement
    Asthma controller step (example)
    Trial of specified alternative controller therapy (e.g., Breo or listed alternatives) required prior to coverage for asthma indications
    ExamplesStep requirement
    Epidiolex / Emsam / Eulexin examples
    Some products require prior trials of specified agents (e.g., two generics for Epidiolex indications; two agents for Emsam; trial of generic bicalutamide for Eulexin)
    ContextRequirement
    Generic alternative trial requirements (general)
    Requires documented trials of specified generic alternatives; exact agents and counts vary by product and indication
    DrugStep requirement
    Fanapt
    Trial of two generic formulary atypical antipsychotics required before coverage for schizophrenia
    DrugStep requirement
    Forteo
    Trial of both specified prior osteoporosis therapies required (e.g., listed agent plus oral bisphosphonate or IV bisphosphonate if intolerant) before coverage
    DrugStep requirement
    Fycompa (Perampanel)
    Trial of two generic agents required prior to coverage
    Product groupRequirement
    Humira indications (examples)
    Prior trial(s) of specified therapies required before approval for several Humira indications (e.g., DMARDs for RA; NSAID for AS); reauthorization requires documentation of clinical response
    ProductsPrerequisite / sequencing requirement
    Ibrance / Iclusig
    Require prerequisite Part D drugs or prior trials / combination use as specified (Ibrance: combination endocrine therapy; Iclusig: prior kinase inhibitor trials or combination with chemotherapy for some indications)
    DrugStep requirement
    Inqovi
    Prior trial of azacitidine required before Inqovi coverage
    Drug / indicationRequirement
    Inlyta — first-line advanced RCC
    Combination immunotherapy required (use with avelumab or pembrolizumab) for first‑line advanced RCC
    Product groupRequirement
    Isotretinoin (Accutane, etc.)
    Prior oral therapy trial required (coverage requires trial of an oral therapy per product-specific notes)
    DrugPrerequisite Part D drug required?
    Ivermectin TABS 3MG
    No prerequisite Part D drug required (criteria does NOT require prior Part D drug)
    ContextNote
    Step therapy (continued examples)
    Other product entries reference required trials or prerequisite therapy in their individual product notes (examples: Jaypirca, Joenja, Jylamvo) — details vary by product and are stated in each entry

    Key Clinical Thresholds and Codes

    Timed 25-Foot Walk (T25FW) — baseline T25FW required prior to initiation
    RequirementBaseline Timed 25-Foot Walk (T25FW) must be documented prior to initiation
    Applies toDalfampridine ER for improvement in MS ambulatory function
    Exclusion noteUse excluded if patient is wheelchair bound or becomes wheelchair bound
    Eosinophil count thresholds — asthma and COPD
    Eosinophil threshold — eosinophilic asthma>= 150 cells/µL at initiation
    Eosinophil threshold — COPD (add-on maintenance)>= 300 cells/µL
    Context

    Definitions and Background

    The Blues' Pharmacy & Therapeutics Committee provides clinical oversight for the formulary and PA criteria. The background statement notes that the committee reviews medical information and recommends the clinical criteria used for authorizations, and the program monitors use to ensure appropriate, cost‑effective therapy.

    Prior authorization definition
    DefinitionPrior authorization (PA): clinical and/or administrative criteria must be met before coverage is provided
    TriggerDrugs subject to PA are identified in the formulary with (PA); failure to obtain PA may result in denial
    How to requestPhysician may contact the pharmacy help desk to request prior authorization
    Step therapy definition
    DefinitionStep therapy (ST): requirement to try one or more formulary drugs prior to coverage of the requested drug

    Denial Risks and Important Warnings

    Note
    Note
    Note
    Note
    Note
    Note
    Note

    Policy Background and Scope

    The policy background emphasizes Pharmacy & Therapeutics oversight: the Blues' P&T Committee evaluates clinical evidence and maintains the clinical criteria applied to formulary prior authorization and step therapy determinations.

    Policy Summary
    Payerblue cross blue shield - michigan
    PolicyAcitretin prior authorization and coverage summary
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateAug 1, 2026
    Last ReviewAug 1, 2026
    Next Review DateAug 1, 2026
    Key ActionSubmit a prior authorization request and required clinical documentation to obtain coverage for acitretin.
    SourceLink
    On This Page
    Coverage Criteria and Product SummariesWhat Providers Must DoInitial Therapy / Start of Therapy ConditionsReauthorization and Duration RulesStep Therapy (Prerequisite Therapy) TableKey Clinical Thresholds and CodesDefinitions and BackgroundDenial Risks and Important WarningsPolicy Background and Scope

    chunk 81

    Cometriq: Indications: All medically-accepted indications; Coverage Duration: One Year; Prerequisite Therapy: Does not require Part D drug.

    chunk 85

    Copiktra: Indications: All medically-accepted indications; Coverage for relapsed or refractory CLL requires at least two prior therapies (Criteria DOES require use of a prerequisite Part D drug).

    chunk 90

    chunk 126

    chunk 169

    Documentation Required

    Prolastin‑c — required diagnostic documentation and age restriction

    Prolastin‑c (alpha‑1‑proteinase inhibitor) requires prior authorization and documentation must include a diagnosis of necrotizing panniculitis or alpha‑1 antitrypsin deficiency with FEV1 < 80% predicted; patients must be 18 years or older.

    • Document diagnosis of necrotizing panniculitis or AAT deficiency with FEV1 < 80% predicted
    • Document congenital AAT phenotype consistent with PiZZ, PiZ (null), or Pi(null,null)
    • Patient age ≥ 18 years
    Step Therapy

    Alunbrig — prerequisite crizotinib required

    Alunbrig is subject to prior authorization for ALK‑positive metastatic disease and requires a prior trial of crizotinib as prerequisite therapy.

    • Prior trial of crizotinib required
    Step Therapy

    Arcalyst — combination prerequisite therapy required

    Arcalyst requires prior authorization and coverage for the recurrent inflammatory indication requires prior use of an inflammatory drug in combination with colchicine.

    • Document trial of an inflammatory drug used in combination with colchicine
    Prior Authorization

    Benlysta — PA and one‑year duration

    Benlysta is subject to prior authorization and, when authorized, coverage duration is one year for medically-accepted indications.

    Prior Authorization

    Betaseron — PA and one‑year duration

    Betaseron requires prior authorization; when authorized, coverage duration is one year for medically‑accepted indications.

    Prior Authorization

    Brukinsa — PA, duration, and prerequisite therapies

    Brukinsa is subject to prior authorization with a coverage duration of one year and requires documented trials of specified prior therapies depending on indication (e.g., Calquence for MCL; anti‑CD20 regimen for MZL; Calquence or Imbruvica for CLL/SLL).

    • MCL: trial of Calquence required
    • MZL: trial of at least one anti‑CD20–based regimen required
    • CLL/SLL: trial of Calquence or Imbruvica required
    Prior Authorization

    Prior authorization and coverage duration — common provider actions

    Prior authorization is required for many listed products; coverage durations are commonly set to one year and some products require documented trials of specified prerequisite therapies prior to approval.

    • Obtain PA where product is marked (PA) on formulary
    • Prepare documentation of prerequisite therapy trials when required
    • Coverage durations commonly authorized for 1 year
    Prior Authorization

    Cayston — PA summary

    Cayston requires prior authorization; indications are listed as all medically‑accepted and coverage duration is 1 year with no prerequisite Part D drug required.

    Prior Authorization

    Cerdelga — PA and duration

    Cerdelga is subject to prior authorization for medically‑accepted indications with a one‑year coverage duration; no prerequisite Part D drug is required.

    Prior Authorization

    Cholbam — PA and one‑year duration

    Cholbam requires prior authorization for medically‑accepted indications; coverage duration is one year and no prerequisite Part D drug is required.

    Prior Authorization

    Clomiphene — PA and duration

    Clomiphene products are subject to prior authorization for medically‑accepted indications; coverage duration is one year and no prerequisite Part D drug is required.

    Step Therapy

    Cobenfy — prerequisite antipsychotic trial required

    Cobenfy requires prior authorization for schizophrenia and mandates prior antipsychotic therapy (prerequisite Part D drug) before coverage will be approved.

    • Document prior antipsychotic therapy
    Step Therapy

    Copiktra — prior therapies required

    Copiktra requires prior authorization for relapsed or refractory CLL and requires documentation of at least two prior therapies as prerequisite treatment.

    • Document at least two prior therapies
    Documentation Required

    Prerequisite Part D drug — confirm and document prior Part D therapy

    Some product entries require use of a prerequisite Part D drug prior to authorization; confirm and document prior Part D therapy when specified in the product PA note.

    • Verify whether product PA notes list a prerequisite Part D drug
    • Provide documentation of prior Part D drug trials when required
    Step Therapy

    Cotellic — vemurafenib prerequisite

    Cotellic coverage for unresectable or metastatic melanoma requires prior authorization and lists vemurafenib as prerequisite therapy; document prior vemurafenib use when applicable.

    • Document prior vemurafenib therapy where indicated
    Prior Authorization

    Deferasirox — one‑year coverage

    Deferasirox is subject to prior authorization and, when authorized, coverage duration is limited to one year.

    Prior Authorization

    Drizalma Sprinkle — one‑year coverage

    Drizalma Sprinkle requires prior authorization and coverage duration when authorized is one year.

    Documentation Required

    Dupixent — PA, duration, and reauthorization documentation

    Dupixent requires prior authorization with indication‑specific criteria; when authorized, coverage duration is one year and reauthorization requires documentation of positive clinical response.

    • Document indication‑specific prior therapies/biomarkers as required
    • Provide evidence of positive clinical response for reauthorization
    Prior Authorization

    Doptelet — PA required

    Doptelet is subject to prior authorization for treatment of chronic immune thrombocytopenia; follow the PA criteria and provide required clinical information per the product note.

    Documentation Required

    Ebglyss — PA, age/weight prerequisites, and Part D requirement

    Ebglyss requires prior authorization and is limited to patients weighing at least 40 kg and aged ≥12 years; coverage duration is one year and some indications require prior Part D drug trials.

    • Document patient weight ≥ 40 kg
    • Document patient age ≥ 12 years
    • Provide evidence of specified prior Part D drug trials when required
    Prior Authorization

    Emgality — PA and duration

    Emgality requires prior authorization for medically‑accepted indications; coverage duration is one year and no prerequisite Part D drug is required.

    Prior Authorization

    Ensacove — PA and duration

    Ensacove is subject to prior authorization for medically‑accepted indications; coverage duration is one year and no prerequisite Part D drug is required.

    Step Therapy

    Epidiolex — PA and required prior trials for seizure indications

    Epidiolex requires prior authorization for medically‑accepted indications; coverage duration is one year and certain seizure indications require documented trials of specified generic alternatives (e.g., two generics for Lennox‑Gastaut; valproic acid/clobazam/topiramate for Dravet).

    • Lennox‑Gastaut: trial of two generic alternatives required
    • Dravet: trial of two of valproic acid, clobazam, or topiramate required
    • TSC‑associated seizures: trial of two generic alternatives required
    Prior Authorization

    Prior authorization and coverage duration — provider checklist

    Prior authorization applies to many products and coverage durations are commonly one year; ensure PA is obtained and document prerequisite therapies or other required clinical information as noted per product.

    • Obtain PA before dispensing when product is marked (PA)
    • Include documentation of prerequisite therapies when product notes require them
    • Note common one‑year authorization duration
    Step Therapy

    Eulexin — generic bicalutamide trial required

    Eulexin requires prior authorization and a documented trial of generic bicalutamide prior to approval; coverage duration when authorized is one year.

    • Document trial of generic bicalutamide
    Step Therapy

    Fanapt — two‑agent antipsychotic trial required

    Fanapt requires prior authorization for schizophrenia and mandates trial of two generic formulary atypical antipsychotics (examples include quetiapine, risperidone, ziprasidone) prior to approval.

    • Document trial/failure of two generic atypical antipsychotics
    Documentation Required

    Fasenra — eosinophil thresholds and reauthorization

    Fasenra prior authorization includes numeric eosinophil thresholds for initiation (≥150 cells/µL for eosinophilic asthma; ≥1000 cells/µL for HES) and coverage duration is one year; reauthorization requires documentation of positive clinical response.

    • Eosinophilic asthma: eosinophils ≥ 150 cells/µL at initiation
    • HES: eosinophils ≥ 1000 cells/µL at initiation
    • Document clinical response for reauthorization
    Documentation Required

    Firazyr — age ≥18 documented for PA

    Firazyr (icatibant) is subject to prior authorization and is limited to patients aged 18 years or older; coverage duration when authorized is one year.

    • Document patient age ≥ 18 years
    Step Therapy

    Fotivda — prior systemic therapy trials required

    Fotivda requires prior authorization for advanced renal cell carcinoma and coverage requires documented trials of two or more prior systemic therapies; provide documentation of prior systemic therapy trials.

    • Document trials of two or more prior systemic therapies for advanced RCC
    Step Therapy

    Fruzaqla — prior chemotherapy and anti‑VEGF required

    Fruzaqla requires prior authorization for metastatic colorectal cancer and coverage requires documented trials of fluoropyrimidine‑, oxaliplatin‑, and irinotecan‑based chemotherapy and an anti‑VEGF therapy; provide required prior chemotherapy documentation.

    • Document prior fluoropyrimidine‑, oxaliplatin‑, and irinotecan‑based chemotherapy
    • Document prior anti‑VEGF therapy
    Prior Authorization

    Fulphila — PA and one‑year duration

    Fulphila requires prior authorization; when authorized, coverage duration is one year and no prerequisite Part D drug is required.

    Documentation Required

    GLP‑1 agonists — PA and documentation requirements

    GLP‑1 agonists are subject to prior authorization; they are excluded if used for weight‑loss only and require submission of medical records confirming a T2DM diagnosis or qualifying laboratory values (A1c ≥6.5%, FPG ≥126 mg/dL, or 2‑hour PG ≥200 mg/dL).

    • Provide chart notes confirming T2DM or lab evidence (A1c ≥6.5% or FPG ≥126 mg/dL or 2‑hour PG ≥200 mg/dL)
    • Do not request coverage if indication is weight loss only
    Prior Authorization

    Prior authorization required — general notice

    Prior authorization is required for the listed products; PA summaries indicate indications are limited to medically‑accepted uses and coverage durations are commonly one year — obtain PA and submit required documentation as specified per product.

    • Obtain PA when product is designated (PA) on formulary
    • Submit required medical information per product PA note
    Prior Authorization

    PA applies — product list

    Prior authorization applies to the listed products and coverage durations are commonly one year; follow each product's PA criteria details and provide requested documentation.

    Step Therapy

    PA requires prerequisite or combination therapy (examples)

    Some prior authorizations require demonstration of specific combination therapies or prior Part D drug trials (examples include Ibrance and Iclusig); document prior combination or prerequisite therapy where required.

    • Ibrance: document combination use with aromatase inhibitor or fulvestrant as specified
    • Iclusig: document prior kinase inhibitor trials or chemotherapy combination per indication
    Prior Authorization

    PA applies — include criteria details

    Prior authorization applies to the listed products; several entries specify 'PA Criteria = Criteria Details' and note coverage duration commonly of one year — ensure PA submission includes the criteria details requested.

    Step Therapy

    Inlyta — combination immunotherapy and prior therapy requirements

    Inlyta prior authorization for first‑line advanced renal cell carcinoma requires combination use with avelumab or pembrolizumab; other Inlyta indications may require a trial of one prior systemic therapy — document combination immunotherapy or prior systemic therapy as applicable.

    • Document combination use with avelumab or pembrolizumab for first‑line advanced RCC
    • Document trial of one prior systemic therapy when applicable
    Prior Authorization

    Ivermectin TABS 3MG — PA and one‑year duration

    Ivermectin 3 mg tablets are subject to prior authorization for FDA‑approved indications; coverage duration when authorized is one year and no prerequisite Part D drug is required.

    Step Therapy

    Step therapy overview — verify and document prior trials

    Step therapy is applied to specified drugs: providers must document trials of required formulary agents (steps) before a PA will be approved when the product's ST requirement is listed.

    • Verify whether the drug is designated (ST) on the formulary
    • Provide documentation of prior formulary drug trials per ST requirements
    Step Therapy

    Balversa — prior systemic therapy trial required

    Balversa requires prior authorization and a documented trial of at least one prior systemic therapy before coverage will be approved.

    • Document trial of at least one prior systemic therapy
    Step Therapy

    Auvelity — generic antidepressant trial required

    Auvelity requires a prior trial of another generic formulary antidepressant as prerequisite therapy before authorization will be granted.

    • Document trial of a generic formulary antidepressant
    Step Therapy

    Braftovi — combination therapy prerequisites

    Braftovi coverage for certain indications requires combination use with specified agents (e.g., vemurafenib + cobimetinib; binimetinib; cetuximab + fluorouracil‑based chemotherapy); document combination regimens when applicable.

    • Document required combination regimens per indication (e.g., vemurafenib + cobimetinib)
    Step Therapy

    Step therapy examples — document specified prior agents

    Step or prerequisite therapy is required for certain products (examples include Brukinsa, Cabometyx); document trials of specified agents (e.g., Calquence for Brukinsa; sorafenib for Cabometyx) when noted.

    • Brukinsa (MCL): trial of Calquence required
    • Cabometyx (HCC): trial of sorafenib required
    • Calquence (MCL): prior therapy required
    Documentation Required

    Prerequisite therapy requirements — document prior trials

    Some products require documented prior therapies before authorization (e.g., Cobenfy requires prior antipsychotics; Copiktra requires at least two prior therapies); include prior therapy documentation in the PA request.

    • Cobenfy: document prior antipsychotic use
    • Copiktra: document at least two prior therapies
    Step Therapy

    Cotellic — vemurafenib prerequisite (provider action)

    Cotellic lists vemurafenib as a prerequisite therapy for coverage in unresectable or metastatic melanoma; document prior vemurafenib use where applicable to support PA.

    • Provide records showing prior vemurafenib therapy
    Prior Authorization

    Deferasirox — one‑year PA duration

    Deferasirox is authorized for a one‑year duration when PA criteria are met; ensure PA includes required clinical information to support a one‑year authorization.

    Prior Authorization

    Drizalma Sprinkle — one‑year PA duration

    Drizalma Sprinkle prior authorization is authorized for one year; include required medical information with the PA request.

    Documentation Required

    Dupixent — PA, one‑year duration, and reauthorization

    Dupixent PA requires indication‑specific documentation and is commonly authorized for one year; for reauthorization submit documentation of positive clinical response.

    • Submit indication‑specific diagnostic and prior‑therapy documentation
    • Provide evidence of clinical response for reauthorization
    Prior Authorization

    Doptelet — PA required

    Doptelet requires prior authorization for its indicated use; include clinical information per the PA note to support authorization.

    Documentation Required

    Ebglyss — PA: age, weight, and prerequisite therapy documentation

    Ebglyss PA requires documentation that the patient is ≥12 years of age and weighs at least 40 kg; some indications require prior Part D drug trials — include age, weight, and prior therapy documentation as applicable.

    • Document patient age ≥ 12 years
    • Document patient weight ≥ 40 kg
    • Provide prior therapy documentation when indicated
    Prior Authorization

    Emgality — PA and one‑year duration

    Emgality requires prior authorization and is commonly authorized for one year; no prerequisite Part D drug is required for coverage.

    Prior Authorization

    Ensacove — PA and duration

    Ensacove requires prior authorization for medically‑accepted indications with a one‑year coverage duration and does not require a prerequisite Part D drug.

    Step Therapy

    Epidiolex — PA and required seizure‑trial documentation

    Epidiolex prior authorization requires documentation of prerequisite trials for specific seizure indications (see product PA: two generic alternatives for Lennox‑Gastaut; two of valproic acid/clobazam/topiramate for Dravet), and coverage duration is one year.

    • Provide trial documentation of required generic alternatives or specified agents per seizure syndrome
    Denial Risk

    Prior authorization and coverage duration — avoid missing documentation

    Prior authorization is commonly required and coverage duration is often one year across many products; include product‑specific prerequisite therapy documentation when requested to avoid denial.

    • Confirm PA designation on formulary
    • Include prior therapy documentation when specified
    Denial Risk

    Eulexin — document bicalutamide trial (denial risk)

    Eulexin requires prior authorization and a documented trial of generic bicalutamide prior to approval; failure to document the bicalutamide trial may lead to denial.

    • Document generic bicalutamide trial to support PA
    Denial Risk

    Fanapt — two‑agent trial required (denial risk if missing)

    Fanapt prior authorization requires documented trials of two generic formulary atypical antipsychotics for schizophrenia; lack of these trials may result in denial.

    • Provide records of two generic atypical antipsychotic trials (e.g., quetiapine, risperidone, ziprasidone)
    Step Therapy

    Forteo — prior osteoporosis therapy documentation required

    Forteo prior authorization requires documented trials of specified prior osteoporosis therapies (e.g., oral bisphosphonate or IV bisphosphonate if intolerant) before approval.

    • Document trials of required prior osteoporosis therapies or inability to tolerate them
    Step Therapy

    Fycompa — two‑agent trial required

    Fycompa (perampanel) requires prior authorization and documentation of trials of two generic agents prior to approval.

    • Document trials of two generic antiepileptic agents
    Denial Risk

    GLP‑1 agonists — documentation required; weight‑loss use excluded

    GLP‑1 agonist PA requires submission of medical records confirming T2DM diagnosis or qualifying lab values; requests for weight‑loss–only use are excluded and will not be authorized.

    • Submit chart notes or lab evidence confirming T2DM (A1c ≥6.5% or FPG ≥126 mg/dL or 2‑hour PG ≥200 mg/dL)
    • Do not submit PA for weight‑loss–only indication
    Documentation Required

    PA requires documentation of combination/prerequisite therapies

    When a product's PA note specifies prerequisite or combination therapy (e.g., Ibrance, Iclusig), document the required combination or prior Part D drug trials to support the authorization request.

    • Ibrance: document combination endocrine therapy as specified
    • Iclusig: document prior kinase inhibitor trials or chemotherapy combination per indication
    Step Therapy

    Inlyta — combination immunotherapy and prior therapy documentation

    Inlyta prior authorization for first‑line advanced RCC requires combination use with avelumab or pembrolizumab and may require a prior systemic therapy trial for other indications; document combination immunotherapy or prior systemic therapy as applicable.

    • Provide evidence of combination use with avelumab or pembrolizumab for first‑line advanced RCC
    • Document prior systemic therapy trials when required
    Documentation Required

    Bronchitol — tolerance test documentation required

    Some products list specific clinical documentation requirements (e.g., Bronchitol requires documentation that the member has passed the Bronchitol tolerance test); include such test documentation with the PA request.

    • Attach Bronchitol tolerance test results when requesting PA for Bronchitol
    Documentation Required

    Document prior therapies — required when PA notes specify

    Document prior therapies when the PA note requires them (examples: Calquence, anti‑CD20 regimens, Imbruvica for Brukinsa indications); absence of documented prior therapy may result in denial.

    • Provide records of prior Calquence, anti‑CD20 regimens, or Imbruvica where applicable
    Documentation Required

    Dalfampridine — baseline T25FW and exclusion for wheelchair‑bound patients

    For Dalfampridine, prior authorization requires documentation of a baseline Timed 25‑Foot Walk (T25FW) prior to initiation; requests for patients who are wheelchair‑bound (or become wheelchair‑bound) are excluded.

    • Include baseline T25FW test results with the PA request
    • Do not authorize if patient is wheelchair‑bound
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Thresholds used to determine eligibility for biologic therapy (e.g., Dupixent indications)
    Eosinophil count threshold — >= 300 cells per microliter
    Threshold>= 300 cells per microliter
    Indication exampleCOPD add-on maintenance requires eosinophils >= 300 cells/µL and continued LABA + LAMA + ICS
    ReauthorizationDocumentation of positive clinical response required for reauthorization
    Minimum patient weight — Ebglyss
    Minimum weight>= 40 kilograms
    Applies toEbglyss (product-specific PA requirement)
    Coverage duration1 Year (per product entry)
    Minimum patient age for Ebglyss
    Minimum age>= 12 years
    Applies toEbglyss (age restriction in product PA)
    Indication noteIndications include atopic dermatitis with prior therapy trials as specified
    Eosinophil count for eosinophilic asthma initiation
    Eosinophil threshold>= 150 cells per microliter at initiation
    Applies toEosinophilic asthma (coverage requires diagnosis and prior controller therapy trials)
    ReauthorizationDocumentation of positive clinical response required
    Eosinophil count for hypereosinophilic syndrome initiation
    Eosinophil threshold>= 1000 cells per microliter at initiation
    Applies toHypereosinophilic syndrome (HES) initiation for Fasenra
    ReauthorizationDocumentation of positive clinical response required
    Age restriction for Firazyr
    Minimum age>= 18 years
    Applies toFirazyr (icatibant) — age restriction in PA criteria
    Coverage duration1 Year (per product entry)
    Bone density T-score threshold referenced for Forteo
    T-score thresholdT-score <= -2.5 (2.5 standard deviations or more below the mean)
    Applies toForteo (teriparatide) — referenced bone density threshold for coverage
    Prerequisite therapyCoverage requires trials of specified prior osteoporosis therapies (oral bisphosphonate or IV if intolerant)
    A1c, FPG, 2-hour PG thresholds
    A1c thresholdA1c >= 6.5%
    FPG thresholdFasting plasma glucose (FPG) >= 126 mg/dL
    2-hour PG threshold2-hour plasma glucose >= 200 mg/dL during OGTT
    IdentificationDrugs that must meet step therapy are identified in the formulary with (ST)
    PurposeEnsures use of appropriate and cost-effective therapy per Pharmacy & Therapeutics Committee guidance
    Alpha-1 antitrypsin deficiency requirements (definition)
    DefinitionAlpha-1 antitrypsin deficiency requirements: documented congenital deficiency consistent with phenotypes PiZZ, PiZ (null), or Pi(null,null) and evidence of symptomatic emphysema or necrotizing panniculitis with FEV1 < 80% predicted
    Age restrictionPatients must be 18 years of age or older (per Prolastin-c entry)
    Prerequisite therapy noteCriteria does not require use of a prerequisite Part D drug for Prolastin-c
    Prerequisite Part D drug (definition)
    DefinitionPrerequisite Part D drug: a previously tried prescription product covered under Part D that must be tried before the specialty drug will be authorized
    UsageSome product entries explicitly require a prerequisite Part D drug (e.g., Brukinsa, Ibrance, Iclusig); others do not (e.g., Cayston, Ivermectin)
    ImpactFailure to document prerequisite Part D drug trials may result in denial of coverage
    EGPA definition
    DefinitionEGPA: eosinophilic granulomatosis with polyangiitis; coverage criteria require diagnosis and typical clinical features to support diagnosis (e.g., eosinophilic vasculitis, neuropathy, pulmonary infiltrates)
    Associated requirementCoverage for EGPA with certain biologics references presence/history of asthma as part of diagnostic criteria
    ReauthorizationDocumentation of positive clinical response required for reauthorization
    HES definition
    DefinitionHES: hypereosinophilic syndrome; policy notes an eosinophil count threshold (>= 1000 cells/µL) for initiation of therapy
    Applies toSpecified in Fasenra PA entry for HES initiation
    ReauthorizationDocumentation of positive clinical response required
    T2DM diagnostic criteria (definition)
    DefinitionT2DM diagnostic criteria: A1c >=6.5%, fasting plasma glucose >=126 mg/dL, or 2-hour plasma glucose >=200 mg/dL during OGTT
    UseAcceptable documentation to support GLP-1 agonist coverage for ongoing treatment of type 2 diabetes mellitus
    ExclusionGLP-1 agonists excluded if used for weight loss only
    Parenteral support dependence (definition)
    DefinitionParenteral support dependence: documentation of dependence on parenteral support for 12 months or greater
    Applies toGattex coverage requires this documentation
    Coverage durationOne Year (per Gattex entry)
    Ibrance combination indication (definition)
    DefinitionIbrance combination indication: HR-positive, HER2-negative advanced or metastatic breast cancer requires combination use with an aromatase inhibitor or fulvestrant as specified
    PrerequisiteCriteria indicates use in combination and may require prerequisite Part D drug trials
    Coverage durationOne Year (per product entry)
    Iclusig indication specifics (definition)
    DefinitionIclusig indication specifics: coverage for newly diagnosed Ph+ ALL requires combination with chemotherapy; other indications may require prior kinase inhibitor trials
    PrerequisiteCriteria does require use of a prerequisite Part D drug for some indications
    Coverage durationOne Year (per product entry)
    PA Criteria, 1 = Criteria Details (summary marker definition)
    DefinitionPA Criteria, 1 = Criteria Details: indicates that detailed prior authorization criteria are defined elsewhere and the line is a summary marker
    ImplicationRefer to full criteria details for clinical requirements when planning authorization requests
    UsageCommonly used throughout product entries in this document
    Coverage Duration (definition) — Ivermectin example
    DefinitionCoverage Duration: the time period for which coverage is authorized; listed as 1 Year for Ivermectin TABS 3MG
    ExampleIvermectin TABS 3MG — Coverage Duration = 1 Year per product entry
    NoteMost product PA summaries in this document list coverage duration as 1 year when specified